New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
08:02 EDTLGNDLigand announces presentation of data from Phase 1 study
Ligand Pharmaceuticals announced that data from a Phase 1 study of the selective estrogen receptor modulator lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago. The presentation provided data from a first-in-human clinical study of lasofoxifene that was performed by Pfizer and recently analyzed by Ligand demonstrating the potent and prolonged effect of a single dose to increase circulating testosterone and gonadotropin levels in healthy young men. Highlights of the presentation include: In an investigator-blinded, randomized, placebo-controlled, single-ascending dose study involving 36 healthy male volunteers, lasofoxifene was well-absorbed after oral administration with peak plasma concentrations reached approximately 6 to 9 hours post-dose and a long elimination half-life of approximately 106 hours; There were no serious adverse events and no clinically significant changes in safety laboratory, vital signs or ECG assessments; Single oral doses of lasofoxifene of 1, 3, 10, 30 and 100 mg increased levels of testosterone; doses of 30 and 100 mg increased levels of T by more than 80%; Levels of luteinizing hormone and follicle-stimulating hormone were also elevated with single oral doses of 30 and 100 mg; Levels of T, LH and FSH peaked between 3 and 7 days post-dose and elevations induced by higher doses were maintained through at least 28 days; T levels plateaued at the high normal range of 30-40 nmol/L between 7 and 28 days post-dose regardless of lasofoxifene dose or LH levels.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2014
11:11 EDTLGNDLigand Q3 pre-announcement unlikely to rally stock, says Cantor
Cantor said its views Ligand's pre-announcement of better than expected Q3 results as no more than "a shuffling of the deck chairs" since the company did not also raise its view for the fiscal year. The firm said it does not expect upward momentum for the stock in the near-term and maintains its Hold rating on the shares.
08:34 EDTLGNDLigand maintains FY14 adjusted EPS $1.50-$1.55, consensus $1.55
Subscribe for More Information
08:33 EDTLGNDLigand sees Q4 revenue $22.5M-$24.5M, consensus $23.54M
08:33 EDTLGNDLigand sees Q3 adjusted EPS 33c-37c, consensus 32c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use